I
n recent years, there has been an increased international effort to reduce the burden of malaria through the implementation and integration of multiple control programs to provide high coverage of affected populations. These efforts have included the use of insecticide-treated bednets, indoor residual spraying, intermittent preventative treatment, rapid diagnostic tests, and artemisininbased combination therapies. Some reduction in malaria morbidity and mortality has been achieved, such that in 2010, the number of clinical cases of malaria worldwide was estimated to be 219 million, with approximately 660,000 deaths (1) . The development of an effective malaria vaccine could bolster these efforts further, but success has been limited. There has been increased interest and emphasis on development and testing of preerythrocytic and transmission-blocking malaria vaccines (2, 3) . RTS,S, the most advanced preerythrocytic vaccine for Plasmodium falciparum, is currently being tested in a large, multicenter phase 3 clinical trial in Africa. Initial reports suggest that vaccine efficacy is only around 30% in the most vulnerable target population of infants (4) , with a higher efficacy of approximately 50% in young children (5) .
The development and testing of blood-stage malaria vaccines have been challenging, and only a limited number of candidate antigens have progressed to evaluation in phase 1 and 2 clinical trials (reviewed in reference 6). Such vaccines are unlikely to prevent infection but may be able to reduce parasite burden, the duration of clinical disease, and/or the severe consequences of malaria associated with mortality. P. falciparum merozoite surface protein-1 (PfMSP1) and apical membrane antigen-1 (PfAMA1) are two of the leading blood-stage vaccine candidates (6) . In clinical trials in human subjects, the efficacy of PfMSP1-and PfAMA1-based vaccines has been low, with problems associated with inadequate immunogenicity, the polymorphism of both B and T cell epitopes, and the short duration of protection (6) (7) (8) (9) (10) . As the ability to evaluate the protective efficacy of blood-stage vaccines requires large and expensive field trials, pursuit of such vaccines appears to be declining in recent years. Nevertheless, an effective blood-stage malaria vaccine could have a very significant impact on reducing the burden of malaria in settings in which it is endemic, even if such a vaccine does not completely prevent infection.
Merozoite surface protein 8 (MSP8) is a target of protective, vaccine-induced antibody responses in the Plasmodium yoelii rodent model of malaria (11) (12) (13) . Proof-of-concept studies showed that a high level of vaccine efficacy against challenge infection with lethal P. yoelii 17XL could be achieved by immunization of mice with a multicomponent vaccine including both P. yoelii MSP1 (PyMSP1) and PyMSP8 (14, 15) . Of interest, this potency was not achieved by immunization with an adjuvanted mixture of recom-binant PyMSP1 and PyMSP8 vaccines. To achieve maximum protection, it was necessary to fuse PyMSP1 19 , a target of neutralizing antibodies, to the N terminus of full-length PyMSP8. Upon immunization, a strong T cell response to epitopes within the PyMSP8 portion of the chimeric antigen was elicited. This T cell response provided help for the production of high and sustained levels of IgG that recognized conformational, protective B cell epitopes of both PyMSP1 19 and PyMSP8 (15) .
MSP8 is well conserved among the species of plasmodial parasites which infect a range of hosts, including rodents, nonhuman primates, and human subjects (16, 17) . Full-length P. falciparum MSP8 contains ϳ600 amino acids, slightly larger than its orthologs in other plasmodial species due to the presence of an asparagine and aspartic acid (Asn/Asp)-rich domain of ϳ170 amino acids near its N terminus. Sequence conservation of PfMSP8 among diverse strains of P. falciparum is very high, with variability mainly restricted to small insertions and/or deletions in the Asn/ Asp-rich domain (16) . In assessing the immunogenicity of fulllength recombinant PfMSP8 (rPfMSP8) and rPfMSP8 (⌬Asn/ Asp), we mapped immunogenic T cell epitopes to highly conserved regions of the protein outside the Asn/Asp-rich domain (18) . The Asn/Asp-rich domain was somewhat immunogenic for B cells, but the majority of immunization-induced antibodies recognized conformational epitopes of PfMSP8 located outside the Asn/Asp-rich region. These antibodies did not exhibit significant functional activity in vitro as measured in a standard parasite growth inhibition assay. The functional activity of these antibodies against P. falciparum blood-stage parasites in vivo has not been evaluated.
Based on the P. yoelii MSP1/8 studies in mice and information gained from immunogenicity studies of rPfMSP8 vaccines in mice and rabbits, we have now produced a chimeric PfMSP1/8 vaccine antigen. In this study, we evaluated the immunogenicity of rPfMSP1/8 for both T cells and B cells, assessed the specificity of the responses for PfMSP1 and PfMSP8 epitopes, and determined the ability of PfMSP1/8-specific IgG to inhibit the in vitro growth of homologous and heterologous strains of P. falciparum bloodstage parasites. In mice and rabbits, we also compared PfMSP1/8 to PfMSP1 42 vaccines to assess differences in the immunogenicity of PfMSP 19 and the induction of cross-strain growth inhibitory antibodies. The results indicate that the chimeric rPfMSP1/8 vaccine antigen has clear vaccine potential, and its further development and testing should be pursued.
MATERIALS AND METHODS
Production and purification of chimeric rPfMSP1/8. To generate the expression construct for the chimeric PfMSP1/8 vaccine, the codon-harmonized gene sequence of PfMSP1 19 (19) was fused to the 5= end of the codon-harmonized gene sequence of rPfMSP8 (⌬Asn/Asp) (18) via a glycine-serine linker (GGSGSG). The sequences of PfMSP1 19 and PfMSP8 from the FVO strain of P. falciparum were utilized. The algorithm for codon harmonization for recombinant antigen expression in Escherichia coli has been previously described (19) and was used effectively to enhance production of full-length rPfMSP8 and rPfMSP8 (⌬Asn/Asp) (18), rPfMSP1 42 (19) , rPfLSA1 (20) , and rPfs48/45 (21) . A leader sequence that includes a histidine tag, MAHHHHHHPGGSGSGT, was incorporated at the N terminus, and two stop codons (TGA and TAA) were added at the 3= end of the chimeric gene. The codon-harmonized synthetic gene was commercially prepared by Blue Heron Biotechnology, Inc. (Bothell, WA), and the DNA was sequence verified. The gene insert was then subcloned into the NcoI and NotI sites of the pET-28 expression vector (EMD Biosciences, San Diego, CA). The PfMSP1/8 expression plasmid was transformed into Shuffle T7 express lysY competent E. coli cells (New England BioLabs, Ipswich, MA). This strain was previously used successfully for the production of full-length, properly folded rPfMSP8 (18) .
Production of rPfMSP1/8 was accomplished in 3-liter bacterial cultures using a BioFLo115 benchtop bioreactor (New Brunswick Scientific, Edison, NJ) as previously described (18) . rPfMSP1/8 expression was induced by the addition of ␤-D-1-thiogalactopyranoside (IPTG; Fisher Scientific, Pittsburg, PA) to a final concentration of 1 mM. Three hours postinduction, cells were harvested by centrifugation at 8,000 ϫ g for 20 min at 4°C, and cell paste was stored frozen at Ϫ80°C. Purification of rPfMSP1/8 followed protocols previously established for both rPfMSP8 and rPfMSP8 (⌬Asn/Asp). Briefly, bacterial cells were lysed using the BugBuster HT protein extraction reagent (EMD Biosciences) in the presence of benzonase nuclease (EMD Biosciences) and recombinant lysozyme (EMD Biosciences). The lysate was clarified by centrifugation, and the resulting pellet was solubilized in column binding buffer (20 mM Tris-HCl, pH 7.9, 5 mM imidazole, 0.5 M NaCl) containing 0.2% Nlauroylsarcosine sodium salt (Sarkosyl; Sigma-Aldrich, St. Louis, MO). rPfMSP1/8 was purified from the detergent-soluble fractions by nickelchelate affinity chromatography on nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Valencia, CA) under nondenaturing conditions as described previously (18) . The eluted rPfMSP1/8 was dialyzed overnight at 4°C against 4 liters of binding buffer containing 0.2% Sarkosyl. The final protein concentration was determined by bicinchoninic acid protein assay (BCA; Thermo Scientific, Rockford, IL). Protein purity and conformation were assessed by Coomassie blue staining following SDS-PAGE on 10% gels, run under both reduced and nonreduced conditions. Corresponding immunoblots were probed with a PfMSP1 19 (18) . Additional antigens used in this study, including rPfMSP8 (⌬Asn/Asp), rPfMSP1 42 , recombinant glutathione Stransferase-PfMSP1 19 (rGST-PfMSP1 19 ) (FVO), and rGST-PfMSP1 19 (3D7), were expressed and purified as previously reported (14, 18, 19, (22) (23) (24) .
Mice and immunization protocols. Male CB6F1/J (BALB/cJ ϫ C57BL/6J) mice or outbred CD1 mice, 5 to 6 weeks of age, were purchased from The Jackson Laboratory and housed in the Animal Care Facility of Drexel University College of Medicine under specific-pathogen-free conditions. All animal studies were reviewed, approved, and conducted in compliance with the Institutional Animal Care and Use Committee (IACUC) of Drexel University College of Medicine. Three immunogenicity experiments were completed. In each experiment, serum and/or splenocytes were recovered from each animal approximately 2 weeks following the last immunization. Experiment 1. Groups of CB6F1/J or outbred CD1 mice (n ϭ 10) were immunized subcutaneously with 10 g/dose of purified rPfMSP1/8 formulated with either (i) 25 g/dose of Quil A as the adjuvant (Accurate Chemical and Scientific Corporation, Westbury, NY) or (ii) combined with 25 g/dose of CpG oligodeoxynucleotide (ODN) 1826 (Eurofins MWG Operon, Huntsville, AL) emulsified in Montanide ISA 720 VG (Seppic Inc., Paris, France) at a ratio of 70:30 (vol/vol) (termed M plus CpG). For all mouse immunizations, rPfMSP1/8 was diluted in saline, resulting in a final Sarkosyl concentration of ϳ0.004%, which did not interfere with emulsification. Control mice were immunized with the corresponding adjuvants alone. All mice were boosted twice at 3-week intervals with the same antigen/adjuvant formulation as that used in the priming immunization.
Experiment 2. Groups of CB6F1/J mice (n ϭ 5) were immunized and boosted 3 weeks later with the following prime-boost antigen combinations: Experiment 3. Groups of CB6F1/J mice (n ϭ 5) were immunized subcutaneously with (i) rPfMSP1/8, (ii) rPfMSP8 (⌬Asn/Asp), (iii) rPfMSP1 42 , (iv) rPfMSP8 (⌬Asn/Asp) plus rPfMSP1 42 , or (v) adjuvant alone. Antigens (10 g/dose) were formulated with either 25 g/dose Quil A as the adjuvant (Accurate Chemical and Scientific Corporation) or combined with 25 g/dose CpG ODN 1826 (Eurofins MWG Operon) and emulsified in Montanide ISA 720 VG (Seppic Inc.) at a ratio of 70:30 (vol/vol). For the rPfMSP8 (⌬Asn/Asp) plus rPfMSP1 42 group, recombinant antigens were combined, formulated with adjuvant, and injected at the same site. Control mice were immunized with the corresponding adjuvants alone. All mice were boosted twice at 3-week intervals with the same antigen/adjuvant formulation as that used in the priming immunization.
T cell proliferation assay. Fifty-one peptides (see Table S1 in the supplemental material) spanning the length of the chimeric rPfMSP1/8 sequence were custom synthesized and purified (GenScript USA Inc., Piscataway, NJ). These peptides overlapped by 9 amino acids and were Ͼ90% pure. Peptides 1 to 11 were based on the PfMSP1 19 (FVO) sequence; peptides 12 and 13 were based on the linker and flanking sequence where PfMSP1 19 and rPfMSP8 (⌬Asn/Asp) were joined; peptides 23 to 60 were based on the rPfMSP8 (⌬Asn/Asp) sequence with peptide numbering consistent with that used in the original publication (18) . The lyophilized peptides were reconstituted to a working concentration of 1 mg/ml as recommended by the manufacturer. T cell proliferation induced by recombinant antigens (5 g/ml) or peptides (15 g/ml) was measured by [ 3 H]thymidine incorporation as previously described (15, 18 ). An additional set of cells was stimulated with 1 g/ml of concanavalin A (ConA; Sigma-Aldrich) or left unstimulated to serve as positive and negative controls. The stimulation index was calculated as the mean counts per minute of stimulated wells divided by the mean counts per minute of unstimulated wells. Measurement of antigen-specific antibody responses by ELISA. The antigen-specific antibody responses induced by immunization with rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), or rPfMSP1 42 were measured by direct binding enzyme-linked immunosorbent assay (ELISA) as previously described (18) . Briefly, ELISA plates were coated with 0.25 g per well of purified rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), rPfMSP1 42 , rGST-PfMSP1 19 (FVO), or rGST-PfMSP1 19 (3D7). Plates were incubated with 2-fold serial dilutions of mouse or rabbit sera starting at 1:2,500. Corresponding adjuvant control sera were used as negative controls and subtracted as background. Bound antibodies were detected by horseradish peroxidase-conjugated rabbit anti-mouse IgG (Thermo Scientific) or goat anti-rabbit IgG (Invitrogen) with ABTS [2,2=-azinobis(3-ethylbenzthiazolinesulfonic acid)] as the substrate. A 405 values between 1.0 and 0.1 were plotted, and titers were calculated as the reciprocal of the dilution that yielded an A 405 of 0.5. A high-titer pool of serum obtained from rPfMSP1/8-immunized mice (n ϭ 5) was included on each assay plate as an internal reference to normalize the data between assays.
Production of polyclonal rabbit antisera. Polyclonal rabbit antisera were generated by Lampire Biological Laboratories (Pipersville, PA) by following their "classic-line basic" protocol. Briefly, adult New Zealand White rabbits (three/antigen) were immunized once with 200 g of either rPfMSP1/8 or rPfMSP1 42 formulated with complete Freund's adjuvant (CFA), followed by 4 booster immunizations (200 g each) with the same antigen formulated in incomplete Freund's adjuvant (IFA). For rPfMSP1/8, a final concentration of ϳ0.01% Sarkosyl did not interfere with emulsification. Approximately 2 weeks after the final immunization, antisera were recovered.
P. falciparum growth inhibition assays. The growth inhibitory activity (GIA) of purified rabbit anti-rPfMSP1/8 IgG and anti-rPfMSP1 42 IgG was assessed in vitro by the measurement of parasite lactate dehydrogenase activity (26) using standard protocols. Prebleed and adjuvant control IgG served as negative controls. Each rabbit IgG was tested at final concentrations ranging between 1.25 and 5 mg/ml as indicated. Growth inhibitory activity was calculated relative to P. falciparum blood-stage parasites growing in complete media in the absence of any added rabbit IgG.
Statistical analysis. When comparing data from two groups, the statistical significance of the differences in antigen-specific IgG titers and T cell proliferation stimulation indices was determined by the Mann-Whitney test. The statistical significance of increases in antigen-specific titers between paired primary and secondary immunization sera was determined using the Wilcoxon signed-rank test. Nonparametric tests were utilized considering the limited ability to ensure normality of the data sets due to sample size. Probability (P) values of Յ0.05 were considered significant.
RESULTS
Expression and purification of chimeric rPfMSP1/8. Based on earlier supporting studies in the P. yoelii rodent model (14, 15) , an effort was initiated to produce and characterize a chimeric MSP1/ 8-based vaccine for P. falciparum. Comparative immunogenicity studies with full-length rPfMSP8 and rPfMSP8 (⌬Asn/Asp) identified the shorter rPfMSP8 (⌬Asn/Asp) as the appropriate fusion partner for PfMSP1 19 (18) . The Asn/Asp-rich domain lacked T cell epitopes and was only weakly immunogenic for B cells, and deletion of the domain did not alter the display of conformational B cell epitopes of PfMSP8. A schematic for the chimeric PfMSP1/8 vaccine is shown in Fig. 1A with the double-EGF-like domains of PfMSP1 19 and PfMSP8 indicated at the N and C termini, respectively. A codon-harmonized gene sequence for the chimeric PfMSP1/8 was synthesized and cloned into the pET28 plasmid. Shuffle T7 express lysY E. coli cells were used as the expression host. rPfMSP1/8 was successfully purified under nondenaturing conditions by nickel-chelate affinity chromatography with a final yield of ϳ2.4 mg/g (wet weight) cells. The quality of the purified product was assessed by SDS-PAGE. In the absence of reducing agent, purified rPfMSP1/8 migrates as a prominent doublet of ϳ48 to 50 kDa with a second higher-molecular-mass band migrating at ϳ100 kDa (Fig. 1B) . This pattern is consistent with that observed previously with rPfMSP8 (⌬Asn/Asp), which contained a single intrachain disulfide bond resulting in a 1:1 mixture of monomers and dimers. Under reducing conditions, rPfMSP1/8 migrated as a single prominent band of ϳ58 kDa, close to its predicted molecular mass. As shown in Fig. 1C , immunoblot analysis performed under nonreducing conditions revealed strong seroreactivity of the 48-to 50-kDa band with MAb 5.2, rabbit antiPfMSP1 19 , and rabbit anti-PfMSP8 antibodies. MAb 5.2 recognizes a conformation-dependent epitope within PfMSP1 19 (27) . The results indicate that the chimeric rPfMSP1/8, displaying correct disulfide-dependent epitopes, could be produced in E. coli and purified in reasonable quantities.
Immunization with rPfMSP1/8 elicits robust T cell responses toward PfMSP8-associated epitopes. Previously, immunization with full-length rPfMSP8 was shown to elicit strong T cell responses to epitopes also present within the shorter rPfMSP8 (⌬Asn/Asp) (18) . PfMSP1 19 has been reported to be poorly immunogenic for T cells due to the difficulty in processing this highly disulfide bond-constrained domain (28) (29) (30) . CB6F1/J mice were immunized three times with rPfMSP1/8 formulated with Quil A as the adjuvant. After a period of rest following the third immunization, splenocytes were harvested and stimulated in vitro with rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), rGST-PfMSP1 19 , or GST alone. Antigen-specific proliferation of T cells was measured in a standard [ 3 H]thymidine incorporation assay. As shown in Fig. 2A , stimulation with rPfMSP1/8 or rPfMSP8 (⌬Asn/Asp) elicited high proliferative responses of cells from rPfMSP1/8-immunized mice that were significantly greater than the responses of splenocytes from adjuvant control mice (P Ͻ 0.01). In contrast, no significant proliferation of cells from rPfMSP1/8-immunized or adjuvant control mice was noted upon stimulation with rGST-PfMSP1 19 or GST alone (P Ͼ 0.1).
The restriction of the rPfMSP1/8-elicited T cell response to epitopes present within the PfMSP8 (⌬Asn/Asp) domain was confirmed. Splenocytes from rPfMSP1/8-immunized and adjuvant control mice were stimulated with a panel of overlapping peptides covering the complete sequence of the chimeric rPfMSP1/8 antigen. Relative to adjuvant controls, T cells from rPfMSP1/8-immunized mice showed significantly higher proliferation in response to 4 dominant peptides (P Յ 0.05) (Fig. 2B ) that mapped to the PfMSP8 (⌬Asn/Asp) region of the chimeric vaccine antigen. Neither PfMSP1 19 -associated epitopes (peptides 1 to 11) nor epitopes present at the linker/junction of the PfMSP1 19 and PfMSP8 (⌬Asn/Asp) sequences (peptides 12 and 13) were immunogenic.
Immunization with rPfMSP1/8 elicits high-titer antibodies to both PfMSP1 19 and PfMSP8. The ability of the PfMSP8-restricted T cell response to provide help for production of antibodies specific for PfMSP1 19 and PfMSP8 B cell epitopes was evaluated. CB6F1/J mice were immunized three times with rPfMSP1/8 formulated with either Quil A adjuvant or with a combination of Montanide ISA 720 and CpG ODN (M plus CpG) as the adjuvant. Sera were collected 2 weeks following the last immunization, and antibody titers to rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), rGSTPfMSP1 19 (FVO), and rGST-PfMSP1 19 (3D7) were determined by ELISA. As shown in Fig. 3A , immunization with the chimeric rPfMSP1/8 elicited high titers of IgG that recognized rPfMSP1/8 as well as epitopes present within the rPfMSP8 (⌬Asn/Asp) domain. Just as important, immunization with rPfMSP1/8 also elicited a very strong antibody response to the homologous rPfMSP1 19 (FVO) domain, which was highly cross-reactive with the heterologous rPfMSP1 19 (3D7) antigen. The use of Quil A as the adjuvant induced somewhat higher titers of antibodies to rPfMSP8 (⌬Asn/ Asp) epitopes than formulations with M plus CpG (P ϭ 0.03). However, titers of antibodies to PfMSP1 19 -specific epitopes were comparable to Quil A and M plus CpG formulations (P Ͼ 0.2).
To determine if the broad specificity of the antibody responses elicited by rPfMSP1/8 was generalizable to genetically diverse populations, outbred CD-1 mice were immunized as described above with rPfMSP1/8 formulated with either Quil A or M plus CpG as the adjuvant. Sera collected 2 weeks following the last immunizations were analyzed by ELISA as described above to determine the response to PfMSP1 19 and PfMSP8 domains. As with inbred CB6F1/J mice, immunization of outbred CD-1 mice with the chimeric rPfMSP1/8 elicited high titers of antigen-specific IgG, and rPfMSP8 (⌬Asn/Asp) epitopes were highly immunogenic (Fig. 3B) . Most importantly, immunization with rPfMSP1/8 also elicited a very strong antibody response to the rPfMSP1 19 (FVO) domain, which again was cross-reactive with the heterologous rPfMSP1 19 (3D7) allele. In contrast to the data from immunization of CB6F1/J mice, differences in mean antibody titers to rPfMSP8 (⌬Asn/Asp) epitopes elicited by immunization of out- Asp), rGST-PfMSP1 19 (FVO), and rGST-PfMSP1 19 (3D7) were measured by ELISA following primary and secondary immunizations. As expected, boosting with rPfMSP1/8 led to a sharp and significant increase (40 to 50-fold) (P Ͻ 0.05) in antibody titers to both PfMSP1 19 and PfMSP8 epitopes (Fig. 4) . A single immunization with PfRBC lysate formulated with Quil A as the adjuvant elicited low titers of antibodies to PfMSP1 19 with little or no response to rPfMSP8 (⌬Asn/Asp)-associated epitopes. Of importance, boosting of rPfMSP1/8-primed mice with PfRBC lysate also led to a significant increase in antibody titers (6-to 10-fold; P Ͻ 0.05) to both PfMSP1 19 and PfMSP8 epitopes (Fig. 4) . Not unexpectedly, the antibody titers to both rPfMSP8 (⌬Asn/Asp) and PfMSP1 19 epitopes following secondary immunization with a heterogeneous mixture of native P. falciparum blood-stage antigens were significantly lower than that observed upon a secondary immunization with rPfMSP1/8 (P Ͻ 0.01). Nonetheless, the data suggest that upon exposure to native, parasite-associated antigen during natural infection, there is the potential for boosting of both PfMSP1 19 -and PfMSP8-specific antibody responses primed by immunization with the chimeric rPfMSP1/8 vaccine.
Comparative immunogenicity of rPfMSP1/8 and constituent single-antigen vaccines. Data from studies of the chimeric MSP1/8 vaccine in the P. yoelii model indicated superiority of rPyMSP1/8 in eliciting strong PyMSP1 19 -specific antibody responses compared to an admixture of two recombinant antigens, rPyMSP1 42 and rPyMSP8 (14) . To evaluate this with the chimeric P. falciparum vaccine, CB6F1/J mice were immunized with rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), rPfMSP1 42 , or a combination of rPfMSP1 42 and rPfMSP8 (⌬Asn/Asp) formulated with Quil A or M plus CpG as the adjuvant. Two weeks following the last immunization, sera were collected and the specificity and titer of elicited antibodies analyzed by ELISA. The antibody responses to rPfMSP1/8 (Fig. 5A ) and rPfMSP8 (⌬Asn/Asp) (Fig.  5B ) elicited by immunization with rPfMSP1/8 or rPfMSP8 (⌬Asn/Asp) alone or the combination of rPfMSP1 42 and rPfMSP8 (⌬Asn/Asp) were consistently strong. Immunization with rPfMSP1/8 elicited high titers of antibodies to PfMSP1 19 , which were highly cross-reactive with FVO and 3D7 alleles of PfMSP1 19 (Fig. 5C to E) , confirming the data presented in Fig.  3 . The titers of PfMSP1 19 -specific antibodies elicited by immunization with rPfMSP1 42 plus Quil A were also comparable to those elicited by immunization with rPfMSP1/8 plus Quil A (P Ͼ 0.30) (Fig. 5D and E) . Most importantly, immunization with a mixture of rPfMSP1 42 and rPfMSP8 (⌬Asn/Asp) resulted in production of high titers of antibodies specific for rPfMSP8 (⌬Asn/Asp) epitopes (Fig. 5B) but markedly inhibited the response to PfMSP1 19 epitopes with the use of Quil A (P Ͻ 0.01) or M plus CpG (P Ͻ 0.01) as the adjuvant relative to that observed with the rPfMSP1/8 vaccine ( Fig. 5D and E) . Consistent with the previous P. yoelii studies, the data indicate that immunization with the rPfMSP1/8 chimeric vaccine promotes superior antibody responses to PfMSP1 19 epitopes relative to immunization with a combined formulation of rPfMSP1 42 and rPfMSP8 (⌬Asn/Asp).
Immunization with rPfMSP1/8 elicits potent, growth inhibitory antibodies against homologous and heterologous strains of P. falciparum. High-titer polyclonal rabbit sera were raised against rPfMSP1/8 and rPfMSP1 42 . As with inbred and outbred strains of mice, immunization of rabbits with rPfMSP1/8 elicited high titers of IgG specific for both PfMSP8 and PfMSP1 19 epitopes (Table 1) . Elicited antibodies were highly cross-reactive between the two major alleles (FVO and 3D7) of PfMSP1 19 . Consistent with previous reports (22, 31, 32) , immunization with rPfMSP1 42 also elicited high titers of antibodies to PfMSP1 19 epitopes, and these were comparable in magnitude to those elicited by rPfMSP1/8 immunization. The functionality of these antibodies was measured by the ability to inhibit the in vitro growth of P. falciparum blood-stage parasites. As shown in Table 2 , rPfMSP1/8-specific antibodies inhibited the growth of homologous (FVO) and heterologous (3D7) strains of P. falciparum by Ͼ90 and Ͼ70%, respectively, when tested at a final concentration of 2.5 mg/ml of IgG. While rabbit sera elicited by immunization with rPfMSP1 42 contained equally high titers of rPfMSP1 19 -specific antibodies, their ability to inhibit the in vitro growth of P. falciparum blood-stage parasites was somewhat less effective and variable, with growth inhibition ranging from 30 to 80% when tested at a final concentration of 2.5 mg/ml IgG ( Table 2) . Testing of higher concentrations of rabbit anti-rPfMSP1/8 and antirPfMSP1 42 IgG (5 mg/ml) resulted in modest increases in growth inhibitory activity (Table 2 ). Background inhibition with prebleed pools and adjuvant control IgG were generally below 10%, with the exception of one sample. Previous studies indicated that rPfMSP8 (⌬Asn/Asp) antibodies do not inhibit the in vitro growth of P. falciparum blood-stage parasites. This was confirmed. As shown in Fig. 6 , the growth inhibitory activity of rPfMSP1/8-specific IgG could be reversed by preincubation of rPfMSP1/8-specific IgG with either rPfMSP1/8 or with GST-PfMSP1 19 (FVO) but not with rPfMSP8 (⌬Asn/Asp).
DISCUSSION
The ability of antibodies to conformational epitopes of MSP1 19 to suppress the growth of blood-stage parasites in vitro and in vivo is well established (24, (33) (34) (35) (36) (37) (38) (39) (40) . This has laid the foundation for the effort to include MSP1 19 as a key component of a blood-stage malaria vaccine. The leading MSP1-based vaccine candidate that has progressed to testing in clinical trials is PfMSP1 42 . This is comprised of the C-terminal PfMSP1 33 and PfMSP1 19 domains of the (47, 48) . In one phase 2 trial completed in Kenyan children, the overall efficacy of an rPfMSP1 42 (3D7) vaccine was limited (10) . In this trial, the possibility that some level of allele-specific protection was elicited is being considered. One approach being considered to address this issue of polymorphism involves immunization with a combined formulation containing multiple alleles of PfMSP1 42 (42, 49) .
Many successful P. yoelii MSP-1 efficacy studies utilized PyMSP-1 19 fused to the glutathione S-transferase of Schistosoma japonicum formulated with a variety of adjuvants (24, 50, 51) . Use immunized with rPfMSP1/8, PfMSP8 (⌬Asn/Asp), rPfMSP1 42 , or a mixture of PfMSP8 (⌬Asn/Asp) and rPfMSP1 42 , formulated with either Quil A or M plus CpG as the adjuvant. Antigen-specific IgG titers (means Ϯ standard deviations) in sera collected following the third immunization were determined by ELISA on plates coated with either rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), rGST-PfMSP1 19 (FVO), or rGST-PfMSP1 19 (3D7) as indicated. For each dilution, the mean absorbance values at A 405 of the pooled sera from adjuvant control mice (n ϭ 5) was subtracted as the background. **, P Ͻ 0.01.
of GST as a heterologous carrier could be eliminated by inclusion of other heterologous T cell epitopes (52, 53) or by 4 to 5 immunizations with nonfused PyMSP-1 19 emulsified in potent adjuvants, including CFA/IFA (37, 54) or M plus CpG ODN (55) (56) (57) . We are unaware of any studies where immunization with nonfused, recombinant PyMSP-1 42 demonstrated comparable protective efficacy. Our efficacy studies with rPyMSP1 42 formulated with Quil A as the adjuvant revealed only partial protection against P. yoelii 17XL malaria (14) . Working with the P. yoelii model, however, we produced and tested a chimeric MSP-based vaccine containing PyMSP1 19 fused to the N terminus of fulllength PyMSP8 (14, 15) . Fusion of PyMSP1 19 to PyMSP8 significantly increased the immunogenicity of PyMSP1 19 over that observed with PyMSP1 42 , with rPyMSP1/8 immunization resulting in the production of high and sustained levels of PyMSP1 19 -specific antibodies. Most importantly, immunization with the chimeric rPyMSP1/8 vaccine formulated with Quil A as the adjuvant elicited nearly complete protection against lethal P. yoelii 17XL. rPyMSP1/8-induced protection was markedly improved over that of vaccines based on single or combined antigen formulations of PyMSP1 42 and PyMSP8. Enhanced protection was attributed to an improved antibody response to PyMSP1 19 and the concurrent targeting of protective, conformation-dependent epitopes present on both PyMSP1 19 and PyMSP8.
We applied our findings in the P. yoelii model to the design and testing of a comparable MSP-based vaccine for P. falciparum. We successfully produced a chimeric recombinant vaccine by fusing rPfMSP1 19 (FVO) to the N terminus of rPfMSP8 (⌬Asn/Asp). Specific selection of rPfMSP8 (⌬Asn/Asp) as the fusion partner was based on comparative T and B cell immunogenicity studies of full-length rPfMSP8 and of rPfMSP8 (⌬Asn/Asp) (18) . We chose two very distinct adjuvants for comparative immunogenicity studies to reduce the possibility that any enhancement in the quantity and/or quality of PfMSP1/8 vaccine-induced responses was unique to a specific formulation. Quil A is a nontoxic, aqueous adjuvant, and its derivative, QS21, has been tested in vaccine trials in human subjects (3, 6) . Montanide is a very different oilbased adjuvant combined with a CpG DNA-based adjuvant designed to promote a Th1-biased response. Our immunogenicity studies with the chimeric rPfMSP1/8 showed remarkable concordance with the earlier data on the P. yoelii MSP1/8 vaccine. Immunization with rPfMSP1/8 induced high titers of antibodies to both PfMSP1 and PfMSP8 epitopes. As anticipated, the T cell response was restricted to epitopes within the PfMSP8 domain but clearly provided adequate help for the activation and differentiation of both MSP1-and MSP8-specific B cells. Immunization with rPfMSP1/8 was superior to immunization with a mixture of rPfMSP1 42 and rPfMSP8 (⌬Asn/Asp) with respect to the production of high titers of PfMSP1 19 -specific antibodies. As a measure of functionality, the rPfMSP1/8-elicited antibodies showed a high level of in vitro growth inhibitory activity against both homologous (FVO) and heterologous (3D7) strains of P. falciparum blood-stage parasites.
Both P. yoelii and P. falciparum MSP8 sequences are highly immunogenic. Our studies show that this is true in both inbred and outbred strains of mice and is not adjuvant dependent. This makes the use of rPfMSP8 (⌬Asn/Asp) as a carrier protein for MSP1 19 very attractive. With the rPfMSP1/8 vaccine, the PfMSP1-specific antibody response is directly focused on the most protective epitopes of the PfMSP1 19 domain. In contrast, immunization with PfMSP1 42 elicits competing antibody responses directed against PfMSP1 33 -associated epitopes which are not clearly linked with protection (54, 58) . T cell responses to epitopes within the PfMSP1 33 domain can provide help for the production of PfMSP1 19 -specific antibodies (29, 59, 60) , but this region of MSP1 is only semiconserved among P. falciparum isolates (47) and can lead to allele-specific responses. Furthermore, there is some evidence that the presence of certain T cell epitopes within PfMSP1 33 impedes the development of memory T cells (61) and/or protective antibody responses to PfMSP1 19 (62) . In the P. yoelii model, improved vaccine efficacy has been demonstrated by replacement of PyMSP1 33 with promiscuous CD4 ϩ T cell epitopes from the N-terminal regions of PyMSP1 (63) . In addition to its high immunogenicity for T cells, the sequence of rPfMSP8 (⌬Asn/Asp) is highly conserved among P. falciparum isolates, effectively eliminating the problem associated with the strain specificity of T cell responses. While our efforts have focused on improving immunogenicity through vaccine design, other efforts in the field have enjoyed recent success in developing and testing new, potent adjuvants for use in human subjects (64, 65) . We are excited about the possibility of further enhancing the immunogenicity of rPfMSP1/8 with the use of adjuvants other than Quil A. Protective antibodies to MSP1 are believed to function by several mechanisms, including blocking merozoite invasion, inhibiting the processing of MSP1 42 , and impairing the intracellular growth of parasites that were opsonized prior to erythrocyte invasion (26, (66) (67) (68) (69) (70) . In vivo, contributing effector mechanisms may also involve other cells and soluble mediators. In vitro, antibodies elicited by immunization with rPfMSP1/8 are highly neutralizing, as measured by GIA against P. falciparum. The rPfMSP1/8 vaccine-elicited antibodies that are functional in the inhibition of P. falciparum growth appear to be specific for PfMSP1 19 exclusively. High titers of PfMSP1 19 -specific antibodies can also be elicited in rabbits by immunization with PfMSP1 42 . However, PfMSP1 42 -elicited antibodies are less effective in inhibiting P. falciparum growth than those elicited by immunization with rPfMSP1/8 when tested at comparable concentrations. This suggests that the fine specificity of PfMSP1 19 -specific antibodies is important for parasite neutralization. Alternatively, immunization with the larger PfMSP1 42 may also elicit the production of blocking antibodies which have been recognized for their ability to hinder the activity of otherwise neutralizing antibodies (66) (67) (68) . As a first step to test this, it will be informative to determine the 50% growth inhibitory concentration of PfMSP1 19 -specific antibodies affinity purified from sera from PfMSP1 42 -versus PfMSP1/8-immunized animals when tested individually and in combination.
The present study indicates that PfMSP8-specific antibodies are not active in the GIA, and this is consistent with our prior report (18) . Previously we showed that antibodies induced by rPfMSP8 (⌬Asn/Asp) immunization predominantly recognized conformation epitopes of the full-length and processed products of native PfMSP8 by immunoblotting (nonreducing conditions) and yielded strong binding in immunofluorescence assays to native PfMSP8 expressed by ring-, trophozoite-, and schizont-stage parasites. However, these PfMSP8-specific antibodies do not inhibit the growth of P. falciparum blood-stage parasites in vitro. As such, we feel it unlikely that the lack of PfMSP8-dependent GIA activity in the present study is due to altered conformation of PfMSP8 in the chimeric PfMSP1/8 antigen. Importantly, we do not know the in vivo mechanism of action of protective MSP8-specific antibodies in the P. yoelii model system. As with MSP1, it is possible that in vivo, anti-MSP8 antibodies could function in cooperation with other components of the immune system, such as complement or FcR-bearing cells. However, it also appears that P. falciparum MSP8 differs to some degree from P. yoelii MSP8 with respect to the timing and extent of proteolytic processing and subcellular localization (18, 71, 72) . The low and/or transient expression of MSP8 epitopes on the surface of extracellular P. falciparum merozoites may limit the ability of PfMSP8-specific antibodies to inhibit the in vitro growth of blood-stage parasites.
Supporting data clearly demonstrate the ability of rPfMSP8 (⌬Asn/Asp) to function as an effective carrier for PfMSP1 19 , leading to the production of high titers of antibodies that effectively inhibit the growth of P. falciparum blood-stage parasites. Upon immunization of human subjects, we anticipate similarly strong CD4 ϩ T cell responses for B cell help, as rPfMSP8 (⌬Asn/Asp) is predicted to contain epitopes that will bind with high affinity to multiple HLA-DR, HLA-DP, and HLA-DQ alleles (73) . From a broader perspective then, it may be worthwhile to consider the use of rPfMSP8 (⌬Asn/Asp) as a carrier for domains of other vaccine candidates that are targets of neutralizing antibodies but are poorly immunogenic. The results presented here also extend our work to specifically develop a chimeric rPfMSP1/8 vaccine. Based on the encouraging data obtained, further testing of this vaccine in immunization and challenge studies in an Aotus monkey model of P. falciparum malaria is being pursued. From such studies, we will also be able to determine if immunization with rPfMSP8 (⌬Asn/ Asp) alone contributes to protection against challenge infection in vivo. These nonhuman primate studies will be important for establishing clear correlates of rPfMSP1/8-induced protection and a foundation to guide further testing. Inhibition of the in vitro growth of P. falciparum FVO blood-stage parasites was assessed by measuring parasite lactate dehydrogenase levels in the presence of rabbit anti-rPfMSP1/8 IgG (rabbits 1 to 3) or adjuvant control IgG. All purified rabbit IgG samples were tested at a constant concentration of 1.25 mg/ml. To test the specificity of growth inhibitory antibodies, anti-rPfMSP1/8 IgG was preincubated with rPfMSP1/8, rPfMSP8 (⌬Asn/Asp), or rGST-PfMSP1 19 (FVO) at an antigen concentration of 100 g/ml. Residual growth inhibitory activity was then measured. No Ag, no antigen.
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